spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

COPA-DATA USA Announces Office Move to Accommodate Accelerated Growth

COPA-DATA



COPA-DATA's New Facility in New Jersey Reinforces Innovative Culture and Commitment to Providing Industry-Leading Technology


COPA-DATA USA, “We are excited to relocate to our new, larger office in New Jersey,” commented Ray Giffen, Managing Director COPA-DATA USA. “This move represents another significant milestone for our company. The new office space better accommodates our growing team and enables us to hire additional talent that will allow us to continue providing industry-leading support and service.”

The new space reflects the innovative culture of COPA-DATA USA and how we strive to make it a great place to work. The facility features technology-enabled conference rooms and stations where teams can collaborate on solutions with colleagues, customers, partners and offsite employees. Other amenities featured are an on-site fitness center, on-site storage, and on-site bus stop to Princeton-Junction train station.

New Address: 50 Millstone Road, Bldg. 400 Suite 150, East Windsor, NJ 08520 USA

Email: sales.us@copadata.com
phone + 43 (0)662 431 002-0
email pharmaceutical@copadata.com
web www.copadata.com/pharmaceutical
email Karolingerstr. 7b 5020 Salzburg Austria
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss

Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
More info >>


White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement